Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary Evive Biotech Ltd’s drug Ryzneuta (efbemalenograstim alfa, F-627) has received marketing approval from the European Commission (EC) in the European Union (EU), following a recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
F-627, a potential first-in-class recombinant human Granulocyte-Colony Stimulating Factor (rhG-CSF), was developed using the proprietary Di-Kine bimolecular technology platform and is known for its long-lasting and potent biological characteristics. Yifan Pharma has secured several licensing deals for F-627. In August 2021, the company granted commercialization rights in mainland China to Chia Tai Tianqing for a consideration of RMB 210 million (USD 29.75 million). In January 2022, distribution rights in Greece and Cyprus were given to KALTEQ S.A. for USD 6.6 million. Apogepha was awarded distribution rights in Germany in a USD 38.9 million deal in February 2022, and LIBBS FARMACÊUTICA LTDA acquired rights in Brazil for USD 6.7 million in March 2022. Later, distribution rights in Switzerland were granted to Apogepha Arzneimittel GmbH in a deal worth USD 6.97 million. The drug received approval in China in May 2023.- Flcube.com
